(Q43837271)

English

A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma

scientific article published in October 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1 reference

based on heuristic

inferred from title

author name string

S Halford

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

D Yip

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

C S Karapetis

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

A H Strickland

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

A Steger

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

H T Khawaja

6

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

P G Harper

7

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

publication date

1 October 2001

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1399-1402

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Estimates of the worldwide mortality from 25 cancers in 1990.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012522120294

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012522120294

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012522120294

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012522120294

7 January 2021

based on heuristic

inferred from DOI database lookup

Liposomal encapsulated anthracyclines: new therapeutic horizons

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012522120294

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012522120294

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012522120294

7 January 2021

based on heuristic

inferred from DOI database lookup

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012522120294

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012522120294

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012522120294

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life assessment in clinical trials--guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience. MRC Cancer Trials Office.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012522120294

7 January 2021

based on heuristic

inferred from DOI database lookup

A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012522120294

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1012522120294

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43837271&oldid=2103767775"